Marcus M. Marcet, MD,
James C. Fleming, MD,
Barrett G. Haik, MD |
Successful Factors in the Use of Botox
Volume 34, Number # 4, 2006 Series
Marcus M. Marcet, MD,
James C. Fleming, MD,
Barrett G. Haik, MD |
1. Carruthers J, Fagien S, Matarasso SL. Consensus Recommendations on the Use of Botulinum Toxin Type A in Facial Aesthetics. Plast Reconstr Surg 2004;114(Suppl):1S-22S.
2. Morgenstern KE, Foster JA. Advances in Cosmetic Oculoplastic Surgery 2002;13:324-330.
3. Lipham WJ. Cosmetic and Clinical Applications of Botulinum Toxin. Thorofare, NJ: Slack; 2004.
4. Ting PT, Freiman A. The story of Clostridium botulinum: from food poisoning to Botox. Clinical Medicine 2004;4(3):258-261.
5. Kaltreider SA, Kennedy RH, Woog JJ, Bradley EA, Custer PL, Meyer DR. Cosmetic Oculofacial Applications of Botulinum Toxin. Ophthalmology 2005;112:1159-1167.
6. Allergan, Inc. Botox Cosmetic (botulinum toxin type A) purified neurotoxin complex (Package Insert). Irvine, CA: Allergan, Inc.
7. Mannor GE. Practical Aspects of Cosmetic Botulinum Toxin. Int Ophthalmol Clin 2005; 45(3):99-106.
8. Spiegel JH. Treatment of Periorbital Rhytids With Botulinum Toxin Type A. Arch Facial Plast Surg 2005;7:198-202.
9. Linder JS, Edmonson BC, Laquis SJ, Drewry RD, Fleming JC. Skin Cooling Before Periocular Botulinum Toxin A Injection. Ophthalmic Plastic and Reconstructive Surgery 2002;18(6):441-442.
|
